Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnqTWM2OD1yLkCwNFI5PyEQvF2= NGLHRmhUSU6JRWK=
LC-2-ad M1XGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XLUGlEPTB;MD6wNFA{OTdizszN MXvTRW5ITVJ?
RL95-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMECwOlY5KM7:TR?= MoDTV2FPT0WU
MZ1-PC M{HCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y1U2lEPTB;MD6wNFA4OjlizszN NF;TOmlUSU6JRWK=
TE-8 M1XXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnmxTWM2OD1yLkCwNVE4KM7:TR?= MnXLV2FPT0WU
SW954 NXTIPFJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMECxNVkh|ryP MmTXV2FPT0WU
TE-11 NXrPc41iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfhTWM2OD1yLkCwNVI{KM7:TR?= MmXtV2FPT0WU
PSN1 NIrwT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvhNlV{UUN3ME2wMlAxOTNizszN MVnTRW5ITVJ?
MOLT-4 NELmTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnaTZVKSzVyPUCuNFAyPDlizszN MXjTRW5ITVJ?
697 M{PicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXKb4Z6UUN3ME2wMlAxOTVizszN M4jQenNCVkeHUh?=
ETK-1 NVLYW3AxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:yXYVPUUN3ME2wMlAxOTV{IN88US=> NH3kOG5USU6JRWK=
TE-10 M{XmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjsWHZvUUN3ME2wMlAxOTV2IN88US=> MX3TRW5ITVJ?
HUTU-80 NFrDcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXETWM2OD1yLkCwNVY5KM7:TR?= NGHxeppUSU6JRWK=
NTERA-S-cl-D1 M3nUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\WSWlEPTB;MD6wNFIxQSEQvF2= NVHJbY41W0GQR1XS
MFH-ino MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:weIdiUUN3ME2wMlAxOjZ6IN88US=> NEnZT2JUSU6JRWK=
IA-LM MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLKd494UUN3ME2wMlAxOjhizszN MVLTRW5ITVJ?
MC116 NF;hU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSyb49KSzVyPUCuNFAzQDlizszN MoXxV2FPT0WU
RKO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnaVnNRUUN3ME2wMlAxOjl6IN88US=> M1H1S3NCVkeHUh?=
MRK-nu-1 NI[1WWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfZN2lIUUN3ME2wMlAxOjl7IN88US=> M2\jXnNCVkeHUh?=
VA-ES-BJ MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnRSI1WUUN3ME2wMlAxOyEQvF2= NVLEflZqW0GQR1XS
KALS-1 NIjX[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTLfY9IUUN3ME2wMlAxOzB6IN88US=> M4L6bHNCVkeHUh?=
BB30-HNC NX;aeoZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMECzNVQh|ryP NVy2WJpPW0GQR1XS
ACN M1vSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi3TFRKSzVyPUCuNFA{OTZizszN M1zrfHNCVkeHUh?=
TE-9 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvOeJpKSzVyPUCuNFA{OjZizszN MYLTRW5ITVJ?
SIG-M5 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvTSGFKSzVyPUCuNFA{OjdizszN NYPGZolUW0GQR1XS
no-10 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGxbWdKSzVyPUCuNFA{PjJizszN M3PRenNCVkeHUh?=
EW-1 M3r5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfUTWM2OD1yLkCwN|cyKM7:TR?= NH\jT4tUSU6JRWK=
SK-LMS-1 NHT1XJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ucGlEPTB;MD6wNFQxOSEQvF2= M2DrRnNCVkeHUh?=
GT3TKB MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:zPYdKSzVyPUCuNFA1OzRizszN NVW0RXdYW0GQR1XS
ES4 NG[wWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLlTWM2OD1yLkCwOFQ6KM7:TR?= M3i0e3NCVkeHUh?=
IMR-5 M3:wVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWflfFlkUUN3ME2wMlAxPDVizszN MWPTRW5ITVJ?
NCI-H1648 M{LzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvU[|NKSzVyPUCuNFA1PjlizszN M3W0[3NCVkeHUh?=
MV-4-11 NXWzNGpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOx[|E2UUN3ME2wMlAxPDd3IN88US=> MnzjV2FPT0WU
SK-UT-1 M4fmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWflNottUUN3ME2wMlAxPDhizszN MkTkV2FPT0WU
NB13 M{TTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXziV|VMUUN3ME2wMlAxPDlzIN88US=> MnXkV2FPT0WU
DJM-1 NXqyWHB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PQRmlEPTB;MD6wNFU{KM7:TR?= MV3TRW5ITVJ?
ES8 M2nYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX75XnU{UUN3ME2wMlAxPTN6IN88US=> M2Dk[3NCVkeHUh?=
TE-6 M3Xzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTETWM2OD1yLkCwOVch|ryP NHnlTpdUSU6JRWK=
KS-1 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nCWGlEPTB;MD6wNFU5OiEQvF2= M3\ObXNCVkeHUh?=
TE-1 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjqOFF5UUN3ME2wMlAxPjB4IN88US=> NXvIS3pwW0GQR1XS
ATN-1 NHeweZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfWTWM2OD1yLkCwOlA6KM7:TR?= NIXvNIhUSU6JRWK=
A4-Fuk NFPPXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrnTWM2OD1yLkCwOlEyKM7:TR?= NIewdYNUSU6JRWK=
ALL-PO MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\aTWM2OD1yLkCwOlMh|ryP MX;TRW5ITVJ?
BE-13 M2\vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjCeJpKSzVyPUCuNFA3OzZizszN NWnhUIpxW0GQR1XS
KM12 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS2W5ZlUUN3ME2wMlAxPjN5IN88US=> MnHEV2FPT0WU
NOS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnWzTWM2OD1yLkCwOlUh|ryP NYm5SWxRW0GQR1XS
SW962 NHrsNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7yTIlKSzVyPUCuNFA3PjJizszN NIHIfWNUSU6JRWK=
OCUB-M M1HBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DtTGlEPTB;MD6wNFY3OiEQvF2= MkXWV2FPT0WU
NCI-H510A MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vsbWlEPTB;MD6wNFY3PSEQvF2= M1TvVXNCVkeHUh?=
EW-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LwcmlEPTB;MD6wNFY6PCEQvF2= MlLIV2FPT0WU
KGN M4HUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEC3NVIh|ryP NGn2O|lUSU6JRWK=
LS-411N M1PDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEC3NVch|ryP NYrFT|hsW0GQR1XS
Becker MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\RXFBGUUN3ME2wMlAxPzJizszN MoK1V2FPT0WU
HC-1 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEC3NlEh|ryP M1jFTHNCVkeHUh?=
CESS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi5WVBKSzVyPUCuNFA4OzdizszN NIDwWVFUSU6JRWK=
KURAMOCHI M1S1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS2TWM2OD1yLkCwO|Q5KM7:TR?= NGLGcpJUSU6JRWK=
TGBC24TKB Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTMcXFKSzVyPUCuNFA4PTJizszN MoL4V2FPT0WU
SW982 M{TtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEC3OlYh|ryP M1W3VHNCVkeHUh?=
HCE-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{OzTWlEPTB;MD6wNFc3PyEQvF2= M3vLOXNCVkeHUh?=
LOUCY M1O3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny1TWM2OD1yLkCwO|c2KM7:TR?= NE\jSVhUSU6JRWK=
8-MG-BA NUDRZZhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvNbYZKSzVyPUCuNFA4QTZizszN NX;KeWdzW0GQR1XS
HT-144 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hte2lEPTB;MD6wNFgh|ryP MXXTRW5ITVJ?
LXF-289 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEC4NVgh|ryP NV3aWo53W0GQR1XS
RS4-11 M1WwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n2emlEPTB;MD6wNFg{PiEQvF2= NXK2NndSW0GQR1XS
DEL M4HUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEC4OFUh|ryP M4CzTXNCVkeHUh?=
OCI-AML2 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILJcJFKSzVyPUCuNFA5PTJizszN Ml\vV2FPT0WU
CCRF-CEM NIH2OZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEC4O|Eh|ryP NX;idFc6W0GQR1XS
A388 M2jiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\aNXZkUUN3ME2wMlAxQDd2IN88US=> MWTTRW5ITVJ?
KNS-42 M2j2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;STWM2OD1yLkCwPFkyKM7:TR?= M4nNXHNCVkeHUh?=
OVCAR-4 NVLqUHVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDWTWM2OD1yLkCwPVA1KM7:TR?= M3LvZXNCVkeHUh?=
NCI-H1355 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnCcHNIUUN3ME2wMlAxQTF2IN88US=> NILa[|FUSU6JRWK=
BL-70 NHzSNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEC5N{DPxE1? NGDEV3pUSU6JRWK=
BL-41 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkixTWM2OD1yLkCwPVM1KM7:TR?= Mlv2V2FPT0WU
A101D Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LpdGlEPTB;MD6wNFk3KM7:TR?= Mmi1V2FPT0WU
HL-60 NVTpWGp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHPbodWUUN3ME2wMlAxQTZ4IN88US=> MmDvV2FPT0WU
COR-L279 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf4e21KSzVyPUCuNFA6QTlizszN M4Tm[XNCVkeHUh?=
NCI-SNU-16 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3voZWlEPTB;MD6wNVAxQCEQvF2= NGHqcYhUSU6JRWK=
Calu-6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMEGwNVIh|ryP MlnuV2FPT0WU
SR MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXodnBKSzVyPUCuNFExOjZizszN NXvMVZl1W0GQR1XS
QIMR-WIL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEGwN|Mh|ryP MWPTRW5ITVJ?
LB647-SCLC M1H6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jXZmlEPTB;MD6wNVA2OSEQvF2= NYrvc2tvW0GQR1XS
RPMI-8226 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX4TY1KSzVyPUCuNFEyODJizszN MW\TRW5ITVJ?
SK-PN-DW M1S0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEGxNVIh|ryP NVfXdW44W0GQR1XS
SF268 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF2wcYhKSzVyPUCuNFEyPTFizszN M{jnTXNCVkeHUh?=
HD-MY-Z MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLQTHJiUUN3ME2wMlAyOTZ|IN88US=> NF;zemFUSU6JRWK=
DOHH-2 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LpNGlEPTB;MD6wNVIxOyEQvF2= MlHBV2FPT0WU
SCC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHiTWM2OD1yLkCxNlA1KM7:TR?= MYjTRW5ITVJ?
ST486 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LDNmlEPTB;MD6wNVIxPCEQvF2= NF3J[lRUSU6JRWK=
NALM-6 M{\Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn3cYlMUUN3ME2wMlAyOjF2IN88US=> MnTIV2FPT0WU
NCI-H1436 M3LWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWntenlEUUN3ME2wMlAyOjNzIN88US=> MXLTRW5ITVJ?
KE-37 MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEGyN|Qh|ryP NIG2W5VUSU6JRWK=
RPMI-8402 Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrUXFljUUN3ME2wMlAyOjV4IN88US=> MWPTRW5ITVJ?
RXF393 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LlO2lEPTB;MD6wNVI2PyEQvF2= M3TQUXNCVkeHUh?=
KARPAS-45 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEGyO{DPxE1? MlOzV2FPT0WU
HOP-62 NImyT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TtVmlEPTB;MD6wNVI4PiEQvF2= MnW0V2FPT0WU
ES1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;6TWM2OD1yLkCxNlg5KM7:TR?= MmDTV2FPT0WU
L-363 M4HSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\xTWM2OD1yLkCxN|UyKM7:TR?= NGLQO5VUSU6JRWK=
GI-1 M1vNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEGzO|Mh|ryP NXTqO3lGW0GQR1XS
CTV-1 NHHOcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvLTWM2OD1yLkCxOFc5KM7:TR?= MYLTRW5ITVJ?
TE-5 NHLHeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S2UWlEPTB;MD6wNVQ6PiEQvF2= MXXTRW5ITVJ?
SNU-C2B M4G2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS0TWM2OD1yLkCxOFk3KM7:TR?= Mor6V2FPT0WU
K-562 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;3WYZKSzVyPUCuNFE2OTZizszN NYXMSYd5W0GQR1XS
SNB75 M3THd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEG1OEDPxE1? M2WyUHNCVkeHUh?=
MOLT-13 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D3WmlEPTB;MD6wNVY{PyEQvF2= M1XQfHNCVkeHUh?=
LS-123 M3\ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEG2OlQh|ryP NV7CeZhnW0GQR1XS
NCI-SNU-5 M1;tOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEG3NFEh|ryP NWXmVmZFW0GQR1XS
Daudi NV7YNJpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTyPG9KSzVyPUCuNFE4ODhizszN M4XGTXNCVkeHUh?=
A253 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO3TWM2OD1yLkCxO|M5KM7:TR?= MkHUV2FPT0WU
TGBC1TKB NXHoc2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLXZFKSzVyPUCuNFE4PTJizszN NX3QVmNyW0GQR1XS
SJSA-1 M{H2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:3N|R7UUN3ME2wMlAyPzZ5IN88US=> NGfv[XdUSU6JRWK=
NCCIT MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMEG3Olkh|ryP M4rHUHNCVkeHUh?=
NCI-H69 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37oN2lEPTB;MD6wNVc4QCEQvF2= MkX3V2FPT0WU
SH-4 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLpTWM2OD1yLkCxPFk2KM7:TR?= MXjTRW5ITVJ?
HCC1187 NWnQPYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHkd3RzUUN3ME2wMlAyQTJ2IN88US=> MkPzV2FPT0WU
HCC1599 M2[xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13T[2lEPTB;MD6wNlAzKM7:TR?= MYHTRW5ITVJ?
ONS-76 M2fHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO3TWM2OD1yLkCyNFM3KM7:TR?= NUX0RWptW0GQR1XS
KU812 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XMTmlEPTB;MD6wNlA{QSEQvF2= MmH6V2FPT0WU
ML-2 NXTVOXJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEKwOFch|ryP MULTRW5ITVJ?
HCE-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfjTWM2OD1yLkCyNFkzKM7:TR?= MUjTRW5ITVJ?
NCI-H446 MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEKxNVIh|ryP M{j2ZXNCVkeHUh?=
RPMI-6666 NWPpNXY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrIT4tKSzVyPUCuNFIyPDlizszN MkS0V2FPT0WU
MOLT-16 NUXL[5l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMEKxOVMh|ryP NGjPemNUSU6JRWK=
JiyoyeP-2003 M3zEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS0PIpKSzVyPUCuNFIyPzZizszN M4LK[3NCVkeHUh?=
MHH-PREB-1 M2PkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\CTWM2OD1yLkCyNVkyKM7:TR?= NXjQTmR1W0GQR1XS
MC-CAR M3fLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zIc2lEPTB;MD6wNlMzPiEQvF2= MX3TRW5ITVJ?
BC-3 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r2NGlEPTB;MD6wNlM1PCEQvF2= M2TVSHNCVkeHUh?=
KINGS-1 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm5TWM2OD1yLkCyN|U2KM7:TR?= NVf4O4FuW0GQR1XS
PF-382 M3TWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEKzO|gh|ryP NI[3d|dUSU6JRWK=
J-RT3-T3-5 M1HMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;Vb3ZKSzVyPUCuNFI{QDNizszN NIPrOnRUSU6JRWK=
SF539 M4fUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET0bXFKSzVyPUCuNFI1ODFizszN NWTG[ZYzW0GQR1XS
LB831-BLC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\G[FVKSzVyPUCuNFI1QDVizszN NGfFe4tUSU6JRWK=
DMS-114 NULOS5BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\USItQUUN3ME2wMlAzPTB{IN88US=> M37BW3NCVkeHUh?=
LB1047-RCC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEK1NUDPxE1? NHqxSZpUSU6JRWK=
LB771-HNC MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjROYF2UUN3ME2wMlAzPTN2IN88US=> MoXjV2FPT0WU
BB65-RCC MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLqeYNiUUN3ME2wMlAzPTN2IN88US=> MUPTRW5ITVJ?
BV-173 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nm[2lEPTB;MD6wNlU2PCEQvF2= NETibWtUSU6JRWK=
ARH-77 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrtTWM2OD1yLkCyOlAyKM7:TR?= MYXTRW5ITVJ?
IST-MEL1 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILtWVRKSzVyPUCuNFI3OjNizszN M1HsenNCVkeHUh?=
NB1 NFXvfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEK2PFch|ryP MmrRV2FPT0WU
EoL-1-cell NXXicZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zmXmlEPTB;MD6wNlY5QCEQvF2= M3jnenNCVkeHUh?=
KY821 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnVTWM2OD1yLkCyOlk4KM7:TR?= MmiwV2FPT0WU
CMK NIPlO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe0OmZKSzVyPUCuNFI4OzRizszN M3fSfHNCVkeHUh?=
NCI-H2126 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEK3Olgh|ryP MnvTV2FPT0WU
NCI-H526 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDQTWM2OD1yLkCyPFkyKM7:TR?= M{nocHNCVkeHUh?=
COLO-684 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHTe4lKSzVyPUCuNFI6ODhizszN MkfyV2FPT0WU
NCI-H747 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XkSGlEPTB;MD6wNlk{OyEQvF2= M120e3NCVkeHUh?=
JAR NGCxVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi2TWM2OD1yLkCyPVQ3KM7:TR?= M4DZZXNCVkeHUh?=
MEG-01 NHjJelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLMTWM2OD1yLkCyPVc5KM7:TR?= NXfr[IRZW0GQR1XS
MONO-MAC-6 M1vQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMEOwNlMh|ryP NXzrNJNsW0GQR1XS
IST-SL1 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\JPXdSUUN3ME2wMlA{ODR{IN88US=> NIDRPGlUSU6JRWK=
CPC-N NYPGfnFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMEOwO|kh|ryP M3LGbXNCVkeHUh?=
NCI-H1963 NHzv[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO1cmpKSzVyPUCuNFMyOzFizszN NGPMXIdUSU6JRWK=
K052 NYGwS2VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v2OGlEPTB;MD6wN|I1PyEQvF2= NHfr[JdUSU6JRWK=
KM-H2 NEP6OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS1VoVNUUN3ME2wMlA{OzB5IN88US=> MVTTRW5ITVJ?
TE-12 M2DWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvS[WdKSzVyPUCuNFM{ODlizszN NIL5emZUSU6JRWK=
TK10 M2jkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO1TnNKSzVyPUCuNFM{PTZizszN MmXiV2FPT0WU
NMC-G1 M4fpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXCTWM2OD1yLkCzOFUzKM7:TR?= MWrTRW5ITVJ?
no-11 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;zUYtKSzVyPUCuNFM1PzhizszN M{n6d3NCVkeHUh?=
NCI-H524 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEO1Nlkh|ryP MnPSV2FPT0WU
MHH-CALL-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32xbmlEPTB;MD6wN|U3OiEQvF2= M2m0[3NCVkeHUh?=
GB-1 MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEO2JO69VQ>? NGPjTZBUSU6JRWK=
OPM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILWWGVKSzVyPUCuNFM3PzNizszN NI\ac25USU6JRWK=
RH-1 M2DmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni4TWM2OD1yLkCzPFE6KM7:TR?= MX3TRW5ITVJ?
NCI-H64 M4ewfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXNUVNHUUN3ME2wMlA{QDV5IN88US=> M{LUXXNCVkeHUh?=
EVSA-T MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfqdmtqUUN3ME2wMlA{QTJ|IN88US=> MVzTRW5ITVJ?
KARPAS-299 NHnvZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDSS5lpUUN3ME2wMlA{QThizszN MWPTRW5ITVJ?
MZ7-mel NH3RSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDZTWM2OD1yLkC0NFQh|ryP NXOyOG9yW0GQR1XS
LB373-MEL-D MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMESxNFUh|ryP M2LKR3NCVkeHUh?=
HEL Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K0ZmlEPTB;MD6wOFE1KM7:TR?= NWfy[m5sW0GQR1XS
SW872 M{O1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvIZXlUUUN3ME2wMlA1OjFizszN MYTTRW5ITVJ?
DU-4475 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zHZWlEPTB;MD6wOFI1PCEQvF2= NHfIdG9USU6JRWK=
IST-SL2 NEjsTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPYTWM2OD1yLkC0Nlc2KM7:TR?= NVS5Z5dyW0GQR1XS
NCI-H82 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHLTWM2OD1yLkC0N|A4KM7:TR?= M{LNOnNCVkeHUh?=
LC4-1 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TvemlEPTB;MD6wOFM2OSEQvF2= NWOyeJM6W0GQR1XS
HDLM-2 NGHWc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjBbXdqUUN3ME2wMlA1Ozl{IN88US=> M1[5U3NCVkeHUh?=
MMAC-SF MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMES1N|Qh|ryP M4\Lb3NCVkeHUh?=
L-540 M1jicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\WcYZKSzVyPUCuNFQ3OzlizszN M2DIRXNCVkeHUh?=
MZ2-MEL NEjCNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7KTWM2OD1yLkC0O|QzKM7:TR?= NInQR2ZUSU6JRWK=
LU-134-A Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLJTWM2OD1yLkC0O|c{KM7:TR?= Ml7HV2FPT0WU
UACC-257 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T3emlEPTB;MD6wOFg1QSEQvF2= M{j0eHNCVkeHUh?=
NCI-H1581 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMES5OVMh|ryP MWjTRW5ITVJ?
NB17 NYHuUm12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXVbWVKSzVyPUCuNFQ6PzlizszN M1XyZXNCVkeHUh?=
SBC-1 M1y1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\0TmlEPTB;MD6wOVA1OiEQvF2= NYXKSHo6W0GQR1XS
TALL-1 MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\YSIlKSzVyPUCuNFUxPDVizszN MX3TRW5ITVJ?
NCI-H1304 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\YTWM2OD1yLkC1NlA5KM7:TR?= M{XSW3NCVkeHUh?=
NEC8 NVfafWlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEWyPFYh|ryP MWHTRW5ITVJ?
CAL-148 NHjsfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvnUHB6UUN3ME2wMlA2PDN7IN88US=> MUXTRW5ITVJ?
CGTH-W-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjNTWM2OD1yLkC1OFQ6KM7:TR?= NV[yWJVkW0GQR1XS
NCI-H889 NFrFdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\QOWZXUUN3ME2wMlA2PTl{IN88US=> MU\TRW5ITVJ?
GR-ST NYDZXIRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELDfXFKSzVyPUCuNFU3OjFizszN MlnzV2FPT0WU
KARPAS-422 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7rTWM2OD1yLkC1OlUh|ryP NICzcppUSU6JRWK=
RPMI-8866 M2TOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq2TW9JUUN3ME2wMlA2PzF{IN88US=> NIfCd4VUSU6JRWK=
SCLC-21H M2HuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zkNWlEPTB;MD6wOVg5PCEQvF2= NWLxcGxLW0GQR1XS
COR-L88 NX3pTJpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jDZmlEPTB;MD6wOVkzPyEQvF2= MlHVV2FPT0WU
LU-139 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS5TWM2OD1yLkC1PVg3KM7:TR?= Mn\oV2FPT0WU
SF126 MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH5ZZpKSzVyPUCuNFYyOzNizszN M1XaWnNCVkeHUh?=
NCI-H1882 M2DxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW4TWM2OD1yLkC2OFI1KM7:TR?= NUnzVlR[W0GQR1XS
EW-24 NYH2THZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTVO|dlUUN3ME2wMlA3PDh|IN88US=> MV;TRW5ITVJ?
CP67-MEL NG\KW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXpNGtzUUN3ME2wMlA3QDFizszN MkDKV2FPT0WU
DG-75 NX3uTlJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwME[4PVkh|ryP M1LvPXNCVkeHUh?=
LOXIMVI NX74R3plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP2TWM2OD1yLkC3NFI5KM7:TR?= NVvZU3BpW0GQR1XS
HH NHrpZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLk[mFKSzVyPUCuNFcyPTdizszN M4jxdXNCVkeHUh?=
K5 NV7QRVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTHZVg6UUN3ME2wMlA4OjJ4IN88US=> M3zDR3NCVkeHUh?=
EC-GI-10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEeyOVch|ryP M37nVnNCVkeHUh?=
SK-N-DZ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fCcGlEPTB;MD6wO|MxPyEQvF2= MYDTRW5ITVJ?
A3-KAW M1j4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jVeWlEPTB;MD6wO|M2OSEQvF2= NEXsXodUSU6JRWK=
MLMA MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fvVGlEPTB;MD6wO|Q3PSEQvF2= MlLXV2FPT0WU
LB996-RCC MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\uOmR4UUN3ME2wMlA4PzB5IN88US=> NEjofGhUSU6JRWK=
OS-RC-2 NXjJN5dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTBZYhEUUN3ME2wMlA4PzR6IN88US=> NEDu[YtUSU6JRWK=
CTB-1 M1LINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;kTWM2OD1yLkC3PFEh|ryP MVXTRW5ITVJ?
IST-MES1 NHruPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHGfGtKSzVyPUCuNFc6OTJizszN M2X5bnNCVkeHUh?=
LS-1034 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;iPJFKSzVyPUCuNFgxOzVizszN MnH3V2FPT0WU
HT M{DIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPKZ3hZUUN3ME2wMlA5ODh4IN88US=> NHvhOmtUSU6JRWK=
NCI-H2141 NUPYb|ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv0UnVKSzVyPUCuNFgyKM7:TR?= NX34cZlyW0GQR1XS
LB2518-MEL NIjlNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMEixOFEh|ryP NUfDcm9KW0GQR1XS
GI-ME-N MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjre4FWUUN3ME2wMlA5PDV{IN88US=> NYjWOJVsW0GQR1XS
TGW MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfrXYxKSzVyPUCuNFg3ODdizszN NIXad2FUSU6JRWK=
SK-NEP-1 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnCXWVKSzVyPUCuNFg3PDFizszN NF7rc25USU6JRWK=
NOMO-1 NV:zemFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEmyO|Uh|ryP MWfTRW5ITVJ?
ES6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDqN49nUUN3ME2wMlA6PTh7IN88US=> MmHLV2FPT0WU
NCI-H209 M2m1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPvfZZKSzVyPUCuNFk4QDZizszN NI\zWpBUSU6JRWK=
GAK M{DrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMUCxOkDPxE1? M4HwN3NCVkeHUh?=
BC-1 NGTudJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfXO5ByUUN3ME2wMlExOzZzIN88US=> NEfGd4dUSU6JRWK=
KLE MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjIe|QxUUN3ME2wMlExPDR|IN88US=> MXTTRW5ITVJ?
EW-3 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnWOoZKSzVyPUCuNVA6QCEQvF2= MnOzV2FPT0WU
NKM-1 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUGxJO69VQ>? NIHxendUSU6JRWK=
D-336MG MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHruVWFKSzVyPUCuNVEzPDRizszN NFL3eHhUSU6JRWK=
NB69 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHGTWM2OD1yLkGxN|AyKM7:TR?= NUfCd2l1W0GQR1XS
D-263MG MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHaZYpKSzVyPUCuNVE4OTJizszN M1fCUXNCVkeHUh?=
KP-N-YS NHX2dmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr0TWM2OD1yLkGyNlkyKM7:TR?= MnfuV2FPT0WU
NCI-H1155 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMUK1OVgh|ryP NGn1dYJUSU6JRWK=
BOKU M3PweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O4[mlEPTB;MD6xNlU4QSEQvF2= NHPodVNUSU6JRWK=
LAMA-84 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHETWM2OD1yLkGyPVkh|ryP NUOyZoxSW0GQR1XS
Raji NG\KZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjGTnB5UUN3ME2wMlE{OTF5IN88US=> NV;rWoVkW0GQR1XS
LU-65 NGT5b4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrKTWM2OD1yLkGzN|A4KM7:TR?= MVnTRW5ITVJ?
NCI-H187 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLT[3NKSzVyPUCuNVM6OjRizszN MlTmV2FPT0WU
GCIY NVvXSWVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfmTWM2OD1yLkG0PVAyKM7:TR?= MmPQV2FPT0WU
NCI-H2107 Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe5WplKSzVyPUCuNVUxQCEQvF2= NVXvN3oyW0GQR1XS
NCI-H1522 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfDTWM2OD1yLkG1NlY3KM7:TR?= M2XaNHNCVkeHUh?=
NB6 NFnxSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPKe4RQUUN3ME2wMlE2PjJ|IN88US=> NHPu[3dUSU6JRWK=
EM-2 NELCTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK0TJZHUUN3ME2wMlE2PzB4IN88US=> NUDPbHFzW0GQR1XS
HCC2218 NWntS2FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\ZSWhKSzVyPUCuNVU6QCEQvF2= NECxSVlUSU6JRWK=
NCI-H748 NGTaXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMU[zO|Yh|ryP NI\OSIVUSU6JRWK=
MS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u3NmlEPTB;MD6xOlU{PyEQvF2= NYX0OmFIW0GQR1XS
NB5 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D4PWlEPTB;MD6xOlU6PyEQvF2= MUnTRW5ITVJ?
OMC-1 MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjPTWM2OD1yLkG2Olg5KM7:TR?= M32zd3NCVkeHUh?=
NCI-H345 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLLd3ZOUUN3ME2wMlE3QTJ6IN88US=> NH7JPGxUSU6JRWK=
L-428 NVnTTXdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\XUHB7UUN3ME2wMlE3QTR3IN88US=> M2\JU3NCVkeHUh?=
SCH NFfzb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzOVoVPUUN3ME2wMlE5Pjh3IN88US=> MmSxV2FPT0WU
NCI-H1417 NHLmUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTRTWM2OD1yLkG5NlI4KM7:TR?= M3zjUnNCVkeHUh?=
COLO-320-HSR MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMUm1N|Ih|ryP MoD5V2FPT0WU
BT-474 M4jOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP3SGU2UUN3ME2wMlIxQDl{IN88US=> MljvV2FPT0WU
GDM-1 M1fxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[wZWlEPTB;MD6yNVk4OSEQvF2= NEO3VohUSU6JRWK=
NCI-H2196 NIXCTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DrRWlEPTB;MD6yNlI{PSEQvF2= MWLTRW5ITVJ?
KP-N-RT-BM-1 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnToTWM2OD1yLkKyN|Q6KM7:TR?= MX\TRW5ITVJ?
KNS-81-FD NYS2c5plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHETWM2OD1yLkKyPVU5KM7:TR?= NYqwe2ZrW0GQR1XS
COLO-668 NXHxTpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NViyN|FbUUN3ME2wMlI{Pjd3IN88US=> M3vKTHNCVkeHUh?=
C2BBe1 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r0N2lEPTB;MD6yOlc1PyEQvF2= NVfsV5hnW0GQR1XS
Ramos-2G6-4C10 NFjsW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3jTWM2OD1yLkK2PVU1KM7:TR?= NUDvcJRYW0GQR1XS
CAS-1 NVXXc2hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;3NoVDUUN3ME2wMlI4ODl4IN88US=> Ml;UV2FPT0WU
GOTO NVPhZY16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTNTWM2OD1yLkK3PFk1KM7:TR?= M4rz[3NCVkeHUh?=
LP-1 NGDPPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjxTIhPUUN3ME2wMlI5ODV5IN88US=> MVPTRW5ITVJ?
NCI-SNU-1 M1qz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqwTWM2OD1yLkK5OFIzKM7:TR?= MU\TRW5ITVJ?
EB-3 NEX6VY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7nTWM2OD1yLkK5PVc6KM7:TR?= NF;xSlZUSU6JRWK=
MHH-NB-11 M3WzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zXdWlEPTB;MD6zNFQxOiEQvF2= NFX3TFVUSU6JRWK=
SK-N-FI M3vW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rBWWlEPTB;MD6zNVY6OiEQvF2= M37kVXNCVkeHUh?=
HCC2157 NIXyPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvJVGVJUUN3ME2wMlM{QTF|IN88US=> NGrzbFZUSU6JRWK=
SIMA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwM{S1PFEh|ryP M2LCWXNCVkeHUh?=
MDA-MB-134-VI MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwM{[5Nlgh|ryP MWHTRW5ITVJ?
NCI-H1694 M4PFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwM{eg{txO MnviV2FPT0WU
EHEB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLKTWM2OD1yLkO5NFg2KM7:TR?= NFPiVG9USU6JRWK=
U-266 NUe2[2g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID1bXBKSzVyPUCuN|k5PDZizszN MVzTRW5ITVJ?
LC-1F Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M163[WlEPTB;MD60N|c3PSEQvF2= NFq5OXJUSU6JRWK=
SHP-77 NXztfJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwNEe4OVUh|ryP MV\TRW5ITVJ?
LS-513 NGP5UWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrSTWM2OD1yLkS5N|A4KM7:TR?= NFXndZFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 3年-20℃
2年-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

文献中の引用 (16)

Frequently Asked Questions

  • Question 1
    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

    Answer: Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ